Cost of Revenue Trends: AbbVie Inc. vs Perrigo Company plc

Pharma Giants' Cost Trends: AbbVie vs Perrigo

__timestamp	AbbVie Inc.	Perrigo Company plc
Wednesday, January 1, 2014	4426000000	2613100000
Thursday, January 1, 2015	4500000000	2891500000
Friday, January 1, 2016	5833000000	3228800000
Sunday, January 1, 2017	7040000000	2966700000
Monday, January 1, 2018	7718000000	2900200000
Tuesday, January 1, 2019	7439000000	3064100000
Wednesday, January 1, 2020	15387000000	3248100000
Friday, January 1, 2021	17446000000	2722500000
Saturday, January 1, 2022	17414000000	2996200000
Sunday, January 1, 2023	20415000000	2975200000
Monday, January 1, 2024	16904000000

In pursuit of knowledge

Cost of Revenue Trends: AbbVie Inc. vs Perrigo Company plc

In the ever-evolving pharmaceutical industry, understanding cost dynamics is crucial. From 2014 to 2023, AbbVie Inc. and Perrigo Company plc have shown distinct trends in their cost of revenue. AbbVie Inc. has experienced a remarkable growth, with its cost of revenue increasing by approximately 361% over the decade. This surge reflects its aggressive expansion and investment in research and development. In contrast, Perrigo Company plc has maintained a more stable cost structure, with only a 14% increase over the same period, indicating a focus on cost efficiency and operational stability.

Key Insights

AbbVie Inc.: Notable spikes in 2020 and 2023, aligning with strategic acquisitions and product launches.
Perrigo Company plc: Consistent cost management, with minor fluctuations, showcasing resilience in a competitive market.

These trends highlight the diverse strategies employed by these pharmaceutical giants in navigating market challenges.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025